NCT05553886

S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction

A Randomized, Double-blind, Positive-drug Parallel Controlled, Multicenter Phase III Trial of the Efficacy and Safety of S086 Tablets in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 5 (estimated)
• Sponsor: Shenzhen People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)

Conditions

• Chronic Heart Failure With Reduced Ejection Fraction

Interventions

Type	Name	Description
DRUG	To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug	To evaluate whether the efficacy of the study drug is noninferior to that of the positive control drug

Timeline

• Start date: 2021-12-21
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2022-09-23
• Last updated: 2022-11-03

Locations

1 site across 1 country: China